Best of ASCO - 2014 Annual Meeting

 

Welcome

Other (Salivary, Thyroid)

Head and Neck Cancer

2019 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A phase 3 (COSMIC-311), randomized, double-blind, placebo-controlled study of cabozantinib in patients with radioiodine (RAI)-refractory differentiated thyroid cancer (DTC) who have progressed after prior VEGFR-targeted therapy.

Marcia S. Brose

TPS6097

A phase II trial cohort of nivolumab plus ipilimumab in patients (Pts) with recurrent/metastatic adenoid cystic carcinoma (R/M ACC).

Vatche Tchekmedyian

6084

A randomized phase II study of pembrolizumab with or without radiation in patients with recurrent or metastatic adenoid cystic carcinoma.

Jonathan Daniel Schoenfeld

6082

ACCURACY: phase (P) 2 trial of AL101, a pan-Notch inhibitor, in patients (pts) with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) with Notch activating mutations (Notchact mut).

Renata Ferrarotto

TPS6098

Activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients with advanced RET-altered thyroid cancers.

Matthew H. Taylor

6018

Ado-trastuzumab emtansine in patients with HER2 amplified salivary gland cancers (SGCs): Results from a phase II basket trial.

Bob T. Li

6001

Alliance A091404: A phase II study of enzalutamide (NSC# 766085) for patients with androgen receptor-positive salivary cancers.

Alan Loh Ho

6020

Analysis of trends in mortality in patients with lymphoepithelial carcinoma of the head and neck.

Marcus Kyle Weldon

e17583

Anaplastic thyroid cancer: A report of six consecutive cases treated successfully with nab-paclitaxel.

Nicholas Travers

e17586

Anlotinib treatment in locally advanced or metastatic medullary thyroid carcinoma: A multicenter, randomized, double-blind, placebo-controlled phase IIB trial.

Dapeng Li

6019

Association between radiotherapy and obstructive sleep apnea in cancer patients: A systematic review and meta-analysis.

Gehad Mohamed Tawfik

e17576

Characteristics of the course of squamous cell carcinoma of the oral cavity depending on the HPV status.

Pavel V. Svetitskiy

e17579

Comparison of mortality trends in patients with non-salivary gland and salivary gland adenoid cystic carcinoma in the United States population.

Girindra Ghanshyam Raval

e17584

Development and validation of a prediction-score model for distant metastases in major salivary gland carcinoma.

Jelena Lukovic

6085

Diagnostic value of cytokeratin-1, survivin and TG expression in circulating tumor cells in the differentiation of benign and malignant thyroid nodules.

Jie Liu

e17575

Efficacy and prognostic factors of systemic therapies for metastatic adenoid cystic carcinoma.

Cyril Roussel-Simonin

e17587

Factors associated with recurrence and death in patients with aggressive hobnail morphology papillary thyroid carcinoma.

Jonathan Matthew Sharrett

e17590

Genomic landscape of FNAs positive for medullary thyroid cancer (MTC) and potential impact on systemic therapy.

Lori J. Wirth

6087

Influence of tumor size and Eastern Cooperative Oncology Group performance status (ECOG PS) at baseline on patient (pt) outcomes in lenvatinib-treated radioiodine-refractory differentiated thyroid cancer (RR-DTC).

Lori J. Wirth

6081

Next Generation Sequencing in Salivary Gland Carcinomas: Do Actionable Mutations Lead to a Therapeutic Advantage? A Multicenter Experience.

Assaf Moore

e17582

NISCAHN: A phase II, multicenter nonrandomized trial aiming at evaluating nivolumab (N) in two cohorts of patients (pts) with recurrent/metastatic (R/M) salivary gland carcinoma of the head and neck (SGCHN), on behalf of the Unicancer Head & Neck Group.

Jerome Fayette

6083

Pilot study combining PD-L1 antibody durvalumab (D) with CTLA-4 antibody tremelimumab (T) and stereotactic body radiotherapy (SBRT) to treat metastatic anaplastic thyroid cancer (ATC).

Eric Jeffrey Sherman

6088

Precision oncology for the treatment of salivary gland tumors.

Damian Tobias Rieke

e17577

PROSPERO: A study to determine the utility of focused genomic profiling to guide selection of drug therapy in salivary gland cancer.

Samuel Rack

6086

Rising thyroid cancer incidence in Kerala: Is it real or over diagnosis?

Saadvik Raghuram

e17589

Safety of denosumab in patients with refractory differentiated thyroid cancer and advanced medullary thyroid cancer.

Johanna Wassermann

e17578

Targeted next-generation sequencing in papillary thyroid carcinoma of Chinese Han population.

Jie Liu

e17574